secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001104659-23-089376
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q2 revenue $57M (-11% YoY), net loss $18.4M; FY guidance $233-243M
---------------------------------------------------------------------------

- Revenue $57.0M, down 11% YoY; net loss attributable to common $20.4M ($0.42/share) vs. $11.2M loss a year ago.
- MVE China revenue fell 67% YoY ($5.8M decline); slower client ramps also hit Biopharma/Pharma segment.
- Bioservices revenue rose 38% to $3.2M; commercial therapy revenue up 9.2% to $4.3M.
- Adjusted EBITDA was -$1.5M, down $7.5M YoY from $6.0M; net loss widened to $18.4M from $9.2M.
- FY2023 revenue guidance $233-243M; cash & short-term investments $504.7M at June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/0001104659-23-089376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/tm2323346d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer